IDENTIFYING PATIENTS AT RISK FOR ADENOMATOUS POLYPOSIS SYNDROMES
Once accurate personal/family history information has been obtained and you identify individuals at risk for adenomatous polyposis syndromes, genetic testing may be appropriate. The American Society of Clinical Oncology (ASCO) issued guidelines for cancer susceptibility testing, which stated that testing should only be offered when:

	The individual has personal or family history features suggestive of a genetic cancer susceptibility condition
	The test can be adequately interpreted
	The results will influence the medical management of the patient or family

The American Gastroenterological Association (AGA) position statement outlines features that indicate a high likelihood that a patient carries an APC mutation and warrants consideration for genetic susceptibility testing. Various articles in the literature discuss recommendations for MAP genetic testing as well. The following criteria capture the AGA guidelines, as well as other recommendations from recent literature.

Candidates for adenomatous polyposis syndromes testing with COLARIS AP ^® are:

	Individuals who are clinically affected with FAP (100 colorectal adenomas)
	Individuals with "multiple" cumulative colorectal adenomas
		Note: AFAP and MAP have been diagnosed in patients with very few polyps (0 to 9), although these conditions are more likely in patients with 10 or more cumulative adenomas.
	Relatives of APC or MYH mutation carriers, as appropriate

Note: Comprehensive COLARIS AP ^® includes analysis of both the APC and MYH genes. Analysis of the MYH or APC genes can be ordered separately as well.

» More